Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT06370065
Phase
PHASE2
Status
Unknown

Conditions

  • Advanced Hepatocellular Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Evaluation of the efficacy and safety of Serplulimab combined with bevacizumab biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) patients

Key Dates

Start date
Apr 27, 2023
Status verified
Apr 2024
Primary completion
Jun 30, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）
    Procedure: HAIC (Hepatic arterial infusion chemotherapy) Drug: HLX10 (PD-1 antibody) Drug: HLX04 (VEGF antibody) HAIC: FOLFOX, q3w, up to 8 times; HLX10: 4.5mg/kg, iv, q3w, ; HLX04: 10mg/kg, iv, q3w.

Primary Outcome Measure

ORR [ Time Frame: up to 1year ]

Central Contacts

Related Studies